Archive | July, 2020

Before Buying a Ticket to a Digital Partnering Event — Know You Have a Shot

23 Jul

By Rory McCann, Marketing Manager & Conference Producer, LSN

Before buying a ticket to a digital partnering event, make sure your goals are realistic and achievable, and those will differ depending on where you are at in the funding universe. (Click here for a free copy of Life Science Nation (LSN)’s Fundraising Manifesto.) The good news is that LSN is hearing from investors that, after a brief slow-down in the early months of 2020, they are closing deals and allocating funds. The big question many are asking is, “Really? Even without face-to-face meetings?” Investors give a resounding, YES!

LSN is tracking 400+ early-stage companies in drugs, devices, diagnostics, and digital health in a diverse range of indications who have raised between $150K – $33M in various funding stages as a direct result of connections made through the Redefining Early Stage Investments (RESI) partnering conferences. While old-school partnering says in-person yearly meetings are the ticket, RESI disagrees, and the numbers don’t lie.

Partnering is an ongoing conversation from pitch to capital allocation, which can often take between 9-18 months. These deals are made through first establishing the fit and then creating an ongoing dialogue that turns into a relationship. This means that it is essential to communicate and meet often via whichever platform is available, which in 2020, is online. Before committing to buying a ticket to a partnering event, it’s important to understand your chances of success, as well as what success looks like for your company, and which investors are truly qualified.

LSN gives early-stage companies a helping hand by having one-on-one interviews regularly with its global investor network to ensure every investor is vetted, as well as runs conferences and an accelerator program, manages databases, and offers a trove of free resources (Next Phase Newsletter, Bootcamps, etc.). LSN has everything an early-stage company needs to get in the game and play to win. Next week’s Digital RESI July dedicated partnering event is one of those resources we hope fundraising CEOs will take advantage of and will join our growing list of innovative companies funded through RESI. Find out more and register for next week’s 2-day dedicated partnering event at https://resiconference.com/digital-resi-two-day-dedicated-partnering-event/.

RESI Featured Companies

23 Jul

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

Life Science Nation (LSN)’s newest 2-day dedicated partnering event begins next week, July 27-28. The Redefining Early Stage Investments (RESI) conference series has been a leader in global partnering events for years, and since digital events have become the only way to connect buyers and sellers, RESI has grown in popularity for its partnering platform, particularly with early-stage companies in the drugs, diagnostics, devices, and digital health (4Ds).

Check out the featured companies at RESI July. Click the logo to learn more about these companies innovating healthcare and life science across the 4Ds. RESI enables early-stage companies to reach a global audience of investors and strategic partners right from their home office, and at an attainable price point for fundraising CEOs. Check out our list of featured companies and remember that there’s still time to register for next week’s event if you want your logo and company story available to eligible investors and strategic partners!

How to Nail a Digital Handshake for Online Investor Meetings

23 Jul

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

In the world of web-based meetings and partnering events, the digital handshake is more important than ever to get in front of the right investors and strategic partners. The introductory message requesting a partner meeting needs to be Step 1 of a 4-step plan to secure meetings with the right people.

In order to fill up your dance card at a partnering conference, you must first and foremost do your homework and read all the profiles of the potential partners. Make sure you only select the ones that are a fit for your company’s stage of development and product set – The Redefining Early Stage Investments (RESI) conference model makes this task very easy because you can search and select these firms by simply clicking through the investor profile filters and produce the target list. That is good news, but the great news is that, at a RESI conference, all the investor profiles are updated and full, meaning that all fundraising CEOs need to do is understand their target investors, review investor profiles based on their criteria, and create a list of potential fits.

Once you get the list of all your target investors, you then must send your first introductory message requesting a meeting. The message is a simple narrative which introduces your firm, with a hook to draw the investor in. This message should include:

  • Your company’s tagline, which nets out in 5-6 words what the firm is and what you do
  • Your elevator pitch that succinctly describes your company and the technology
  • What differentiates your technology or product innovation, and how that will affect your target market
  • Information on your raise and target milestones
  • Any other noteworthy net/net items about you or your team

Put this together and press send. It doesn’t have to be a long, drawn-out document, just a crisp message that provides enough info so that the reader can determine if you are a fit and that they should say yes to a meeting. By making your message short and concise, you show the recipient that you respect their time, understanding that they are receiving hundreds of requests, and that you did the work to make it easy for them to decide to meet.

Following up is crucial in securing partnering meetings. Each follow-up message should be short and a “quick ping” in nature. Life Science Nation (LSN) recommends that you follow this order:

  • Your second message should be on the product/technology you have created, why it is different and how your IP is a game changer. Once again, net out your differentiated value.
  • Your third message should be a quick ping on key management, highlighting you or a noted team member’s experience that has moved the needle and made your company unique.
  • Your fourth message should include your one-page tear sheet, which has all the previous messages on one page.

This is a process LSN has developed and knows works – We have the metrics to prove it. Countless times, through the coaching that LSN provides to CEOs from our Focus on Cures Accelerator, we have seen the meeting numbers jump from 4-6 meetings to 8-12 per day. It works, and there is still time to sign up for the next RESI dedicated partnering event, July 27-28. Click here to sign up and to practice that digital handshake!

Hot Investor Mandate: Global Provider of Life Science Services & Equipment Strategically Partners and Invests In Diagnostics and Life Science Tools

23 Jul

A global leader in life sciences, diagnostics and applied chemical markets providing services, equipment, and support solutions to laboratories worldwide has an Early Stage Partnership Program that works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit the firm’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.

The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Cellular Reprogramming, Cellular Manufacturing/Bioprocessing, Data Analytics, Informatics, Molecular Diagnostics, Omics, Single Cell Analysis and Systems Biology. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.

The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Invests Up to €10M Across Broad Life Science & Healthcare Sectors

23 Jul

A firm based in Western Europe focuses on investment opportunities in Europe but is open to considering investments in China as well. Initial equity-investments range in size from € 1 million up to € 10 million.

The firm invests broadly within the healthcare sector, and manages funds in Health-tech, Sustainable Chemistry, Digital Growth (with a focus on digital health and Industry 4.0).

The firm’s funds invest in companies that are in revenue stage or pre-revenue stage provided that the technologies and products are disruptive and have the potential to significantly address global markets.

The firm looks for exceptional management teams but is ready to support its portfolio companies in building their organization and being a sparring partner for strategy and business development discussions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Vehicle of Angel Group Seeks Early-Stage Companies Across All Life Science Sectors and Assists China Market Entry

23 Jul

The main investment and operation vehicle of an angel group was formed on the basis of investing in passionate early-stage entrepreneurs developing novel technologies. The firm’s areas of interest include AI, big data, pharmaceuticals, healthcare, wearable devices, etc. The firm has invested in academic spin-offs from Harvard and MIT as well.

The firm has three sub-entities that work closely together in order to find valuable US high-tech startups, conduct rigorous screening, help them with accelerated growth and expand into the Chinese market, as well as providing exit strategy guidance.

The firm is interested in a wide range of life science areas. The firm will look at Therapeutics, Medical Devices, Digital Health, and Diagnostics. The firm seeks to invest in early-stage companies, within therapeutics, the firm will look at stages before phase I.

The firm has no specific company or team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA VC Fund Invests Up to $10M in High Growth Healthcare IT Companies That Deliver Value-Based Care

23 Jul

A venture capital fund based in USA leads investments in high growth, mostly US-based Healthcare IT, SaaS, PaaS and technology-enabled service businesses. The firm has a flexible model to right-size equity investments with initial investments typically around $10M. The firm is active in governance and seeks to remain involved through multiple financing rounds. The fund targets a 5-year investment window.

The fund investments are focused on a few key themes in businesses that improve the human condition and deliver value-based care.  It seeks investments in B2B or B2B2C companies with proven business models and experienced teams pursuing end-market opportunities large enough to support creation of companies with $1B in enterprise value. Thematic areas of focus include personalized medicine, patient navigation, referral management, and enablement of payer-provider risk sharing.

The firm is open to work with management teams with various levels of experience. The fund does seek a board seat along with investment and prefers to be fairly involved with the management team and strategy of the company. The fund does not purchase secondary shares of a company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.